Send to

Choose Destination
Horm Metab Res. 2018 May;50(5):403-407. doi: 10.1055/a-0591-9442. Epub 2018 May 4.

Sequential Treatment Escalation with Dapagliflozin and Saxagliptin Improves Beta Cell Function in Type 2 Diabetic Patients on Previous Metformin Treatment: An Exploratory Mechanistic Study.

Author information

Clinical Research Services, Mannheim, Germany.
Johannes Gutenberg University Mainz, 1st Medical Department, Endocrinology, Mainz, Germany.
Johannes Gutenberg University Mainz, Surgical Department, Mainz, Germany.
Profil Institut für Stoffwechselforschung, Neuss, Germany.
MLM Medical Labs, Moenchengladbach, Germany.
Profil Mainz GmbH & Co. KG, Mainz, Germany.


We investigated the effect of sequential treatment escalation with dapagliflozin and saxagliptin on beta cell function in patients with T2DM insufficiently controlled on metformin monotherapy during a hyperglycaemic clamp investigation. Twenty-six patients (19 males, age 63.5±7.0 years; duration of diabetes 8.8±4.7 years; HbA1c 63.9±15.8 mmol/mol; mean±SD) were enrolled in the study. During a first treatment period (TP1) all patients received 10 mg dapagliflozin for one month, followed by the addition of 5 mg saxagliptin or placebo for another month (TP2). At baseline and at the end of each treatment period, fasting glucose and insulin levels were analysed, and a hyperglycaemic clamp with the measurement of plasma C-peptide, insulin, proinsulin, and glucagon was performed. Treatment with dapagliflozin reduced fasting glucose levels and insulin resistance (TP1). Within the hyperglycaemic clamp, C-peptide and insulin concentrations increased after the addition of dapagliflozin in TP1 (0.48±0.45 nmol*h/l; 6.24±17.9 mU*h/l) and further improved after the addition of saxagliptin in TP2 (0.38±0.34 nmol*h/l; 6.59±10.15 mU*h/l). Acute insulin response did not change after the addition of dapagliflozin (TP1), but significantly improved after the addition of saxagliptin in TP2 (0.89±0.76 mU*h/l). Both drugs improved the C-peptide/proinsulin ratio. After the addition of saxagliptin, the glucagon/insulin ratio significantly declined (TP2). Treatment escalation with dapagliflozin and saxagliptin exhibit additive effects on beta cell capacity, and improves alpha and beta cell integrity.

[Indexed for MEDLINE]

Conflict of interest statement

TF has received honoraria for consulting and scientific presentations from Astra Zeneca, Boehringer Ingelheim, Eli Lilly, Novo Nordisk, Sanofi, and Novartis. AF and LPM are employees of Profil. TH and CK are shareholders of Profil, which received research funds from Adocia, AstraZeneca, Becton Dickinson, Biocon, Boehringer Ingelheim, Dance Biopharm, Eli Lilly, Grünenthal, Gulf Pharmaceutical Industries, Johnson & Johnson, Marvel, MedImmune, Medtronic, Novartis, Novo Nordisk, Roche Diagnostics, Sanofi, Senseonics and Zealand Pharma. In addition, TH is member of advisory panels for Novo Nordisk and received speaker honoraria and travel grants from Eli Lilly, Mylan and Novo Nordisk. MMW has received honoraria for consulting and speaking from Boehringer Ingelheim, Eli Lilly, AstraZeneca, Novartis, Novo Nordisk and is member of advisory panels for Novo Nordisk, Eli Lilly, and Novartis. SV and MKA declared no conflict of interest.

Supplemental Content

Full text links

Icon for Georg Thieme Verlag Stuttgart, New York
Loading ...
Support Center